Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on…
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research…
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care…
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin…
LEO Pharma Presents New Long-Term Data for SPEVIGO® (spesolimab-sbzo) in Adults with Generalized Pustular Psoriasis at AAD 2026 LEO Pharma A/S has announced new long-term clinical data supporting the use…
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively…
Enveric Biosciences Announces Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Enveric Biosciences, a biotechnology company focused on developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders,…
Angelalign Technology Reports 2025 Results, Highlighting Clinical Excellence as a Key Driver of Global Expansion Angelalign Technology Inc. (6699.HK) has announced its financial results for the fiscal year 2025, reporting…
Lantern Pharma Reaffirms Panna Sharma’s Ongoing Role as President and CEO; Warns Investors of Misleading Third-Party Report Lantern Pharma Inc., an AI-driven oncology company focused on transforming cancer drug development…
Ono Pharma Files for Approval of Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors in Japan Ono Pharmaceutical Co., Ltd. has announced the submission of a regulatory application in Japan…
Neurocrine Biosciences Unveils First Expert Consensus Guidelines for Managing Tardive Dyskinesia in Long-Term Care Settings Neurocrine Biosciences, Inc. today announced the presentation of the first expert consensus recommendations focused on screening,…